news

FDA approves Helicobacter pylori infection treatment

63
SHARES

The US FDA has granted approval for the marketing authorisation of Talicia, intended to treat adults with H. pylori infection.

The US Food and Drug Administration (FDA) has approved Talicia® (omeprazole magnesium, amoxicillin and rifabutin) for the treatment of Helicobacter pylori infection in adults.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

…the medication should only be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria”

Talicia, produced by Redhill Biopharma, is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria to current clarithromycin-based standard-of-care therapies.

The drug is a delayed-release, novel, fixed-dose oral capsule that is a combination of two antibiotics and a proton pump inhibitor (PPI).

The approval is based on two Phase III studies which saw positive results for the drug. The confirmatory study demonstrated 84 percent eradication of H. pylori infection with Talicia, compared to 58 percent in the active comparator arm.

“The FDA’s approval of Talicia demonstrates our unwavering dedication to patients suffering from gastrointestinal diseases. We thank the patients, researchers and clinical staff who participated in the studies of Talicia,” said Dror Ben-Asher, Chief Executive Officer of RedHill Biopharma. 

However, the company has emphasised that to reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, the medication should only be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

The pharmaceutical company expects to launch the drug in the US in early 2020.

Share via
Share via